Author

Márta Széll

University of SzegedORCID 0000-0002-0730-714XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrew Michael FreyiD· 1 shared Andrew PauliD· 1 shared Aurelio A. TelemaniD· 1 shared Christopher J. LordiD· 1 shared Christopher P. A. T. LawsoniD· 1 shared Christos GonidasiD· 1 shared Constantinos DemetriadesiD· 1 shared David R. AdamsiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew Michael FreyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity

Stephanie Fernandes, Jiyoung Pan, Diana S. Terziyska, Seda Koyuncu, Xiaolei Ding, István Balázs Németh, Sabine Wilhelm, Julian Nüchel, Suzan Al-Gburi, Christos Gonidas, Manolis Pasparakis, George Mosialos, Márta Széll, Aurelio A. Teleman, Sabine Anne Eming, , Constantinos Demetriades

This study identifies CYLD as a deubiquitinase that inhibits mTOR activity by removing K63-linked ubiquitin chains, linking its loss to mTOR hyperactivation and disease.

bioRxiv · Sep 1, 2025 · PreprintCell Biology

Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.

Kirsty Hodgson, Joseph Inns, Gary Reynolds, Emily Stephenson, Andrew Paul, Naomi Sinclair, Giacomo Berretta, Christopher P. A. T. Lawson, Andrew Michael Frey, Iglika G. Ivanova, Éva Ádám, Christopher J. Lord, Simon Cockell, Jonathan M Coxhead, Nikoletta Nagy, , Neil Rajan

This study identifies non-canonical NF-κB signalling as a therapeutic target in CYLD cutaneous syndrome and shows that IKK inhibition reduces tumor viability in patient-derived models.

bioRxiv · Jan 31, 2025 · PreprintCancer Biology